PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight
The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical trials such as vepdegestrant (Arvinas and Pfizer), luxdegalutamide (Arvinas and Novartis), ASP3082 (Astellas Pharma), DT2216 (Dialectic Therapeutics), and others, along with increasing applicability in neurodegenerative and inflammatory diseases, are further fueling sustained R&D investment.
LAS VEGAS, Feb. 10, 2026 /PRNewswire/ -- DelveInsight's PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as HR+/HER2− Breast Cancer, Triple Negative Breast Cancer (TNBC), Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging PROTAC, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
Key Takeaways from the PROTAC Market Report
Discover PROTAC market CAGR and revenue projections @ https://www.delveinsight.com/sample-request/protac-market-forecast?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the PROTAC Market
PROTAC Market Analysis
Learn more about PROTACs in oncology vs other indications @ PROTAC Analysis
PROTAC Competitive Landscape
Emerging players such as Arvinas and Pfizer (Vepdegestrant), Arvinas and Novartis (Luxdegalutamide), Astellas Pharma (ASP3082), Dialectic Therapeutics (DT2216), and others are evaluating drugs in clinical trials.
Arvinas and Pfizer's Vepdegestrant is an investigational, orally bioavailable PROTAC-based protein degrader engineered to selectively eliminate the estrogen receptor and is being developed for the treatment of ER+/HER2– breast cancer. In July 2021, Arvinas entered into a global partnership with Pfizer to jointly develop and commercialize vepdegestrant, with the two companies sharing worldwide development costs, commercialization expenses, and profits.
Arvinas and Novartis' ARV-766 is an investigational, orally bioavailable PROTAC protein degrader designed to selectively target and degrade the androgen receptor. In preclinical studies, ARV-766 has shown activity across models expressing wild-type androgen receptor as well as tumors harboring androgen receptor mutations or amplification, key mechanisms associated with resistance to existing androgen receptor–directed therapies. ARV-766 is currently being evaluated in a Phase II clinical trial for metastatic prostate cancer. In April 2024, Arvinas entered into an exclusive global licensing agreement with Novartis for the development and commercialization of ARV-766. The transaction also included an asset purchase agreement under which Novartis acquired Arvinas' preclinical AR-V7 program.
Astellas Pharma's ASP3082 is a PROTAC molecule that selectively degrades the KRAS G12D protein and represents the first targeted protein degrader to advance into clinical development for this target. It has the potential to become a first-in-class therapy for solid tumors driven by KRAS G12D mutations. A Phase I clinical trial is currently ongoing in patients with KRAS G12D–mutant solid tumors, with proof-of-concept data expected in the first half of calendar year 2025. The company is preparing to advance the program into registration trials.
The anticipated launch of these emerging therapies are poised to transform the PROTAC market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the PROTAC market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about pipeline PROTAC drugs and commercial potential, visit @ PROTAC Treatment
Recent Developments in the PROTAC Market
What are PROTACs?
PROTACs (PROteolysis TArgeting Chimeras) are an emerging class of therapeutic molecules designed to selectively degrade disease-causing proteins rather than merely inhibiting them. They are heterobifunctional compounds that simultaneously bind a target protein and an E3 ubiquitin ligase, bringing the two into close proximity and triggering ubiquitination of the target protein. This process marks the protein for destruction by the cell's natural proteasome system. By eliminating the protein entirely, PROTACs can achieve deeper and more sustained biological effects, overcome resistance seen with traditional inhibitors, and enable targeting of previously "undruggable" proteins. As a result, PROTAC technology is gaining significant traction across oncology, immunology, and other therapeutic areas.
PROTAC Epidemiology Segmentation
The PROTAC market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020–2034 across the leading markets. The PROTAC target patient pool is segmented into:
PROTAC Report Metrics
Details
Study Period
2020–2034
PROTAC Report Coverage
7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Indications Covered in the Report
HR+/HER2− Breast Cancer, Triple Negative Breast Cancer (TNBC), Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), and others
PROTAC Target Patient Pool Segmentation
Total Cases of Selected Indications for PROTAC, Total Eligible Patient Pool for PROTAC in Selected Indications, and Total Treated Cases in Selected Indications for PROTAC
Key PROTAC Companies
Arvinas (NASDAQ: ARVN), Pfizer (NYSE: PFE), Novartis (SWX: NOVN), Astellas Pharma (TYO: 4503), Dialectic Therapeutics, and others
Key PROTACs
Vepdegestrant, Luxdegalutamide, ASP3082, DT2216, and others
Scope of the PROTAC Market Report
Discover emerging technologies for PROTAC design @ PROTAC Clinical Trials
Table of Contents
1
PROTAC Market Key Insights
2
PROTAC Market Report Introduction
3
Executive Summary
4
Key Events
5
Epidemiology and Market Forecast Methodology
6
PROTAC Therapies Market Overview at a Glance
6.1
Clinical Landscape (Analysis by Molecule Type, Phase, and Route of Administration [RoA])
6.2
Market Share (%) Distribution by Indications of PROTAC Therapies in 2028
6.3
Market Share (%) Distribution by Therapies of PROTAC Therapies in 2036
7
Background and Overview
8
Treatment Guidelines
9
Epidemiology and Patient Population
9.1
Key Findings
9.2
Assumptions and Rationale: 7MM
9.3
Epidemiology Scenario in the 7MM
9.3.1
Total Cases of Selected Indications for PROTACs in the 7MM
9.3.2
Total Eligible Patient Pool for PROTACs in Selected Indications in the 7MM
9.3.3
Total Treated Cases in Selected Indications for PROTACs in the 7MM
10
Emerging PROTAC Drugs
10.1
Key Cross Competition
10.2
Vepdegestrant (ARV-471): Arvinas and Pfizer
10.2.1
Product Description
10.2.2
Other Development Activities
10.2.3
Clinical Development
10.2.3.1
Clinical Trial Information
10.2.4
Safety and Efficacy
10.2.5
Analyst's Views
10.3
Luxdegalutamide (ARV-766): Arvinas and Novartis
List to be continued…..
11
PROTAC Therapies Market: Seven Major Market Analysis
11.1
Key Findings
11.2
PROTAC Market Outlook
11.3
Conjoint Analysis
11.4
Key PROTAC Market Forecast Assumptions
11.5
Total PROTAC Market Size by Country in the 7MM
11.6
Total PROTAC Market Size by Indications in the 7MM
11.7
Total PROTAC Market Size by Therapies in the 7MM
11.8
The United States PROTAC Market Size
11.8.1
Total PROTAC Market Size by Indications in the United States
11.8.2
Total PROTAC Market Size by Therapies in the United States
11.9
EU4 and the UK PROTAC Market Size
11.1
Japan PROTAC Market Size
12
PROTAC Market Unmet Needs
13
PROTAC Market SWOT Analysis
14
KOL Views on PROTAC
15
PROTAC Market Access and Reimbursement
15.1
The United States
15.2
In EU4 and the UK
15.3
Japan
15.4
Summary and Comparison of Market Access and Pricing Policy Developments in 2025
15.5
Market Access and Reimbursement of PROTAC Therapies
16
Bibliography
17
PROTAC Market Report Methodology
Related Reports
Non-small Cell Lung Cancer Market
Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including Daiichi Sankyo, AstraZeneca, Gilead Sciences, BieGene, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda Pharmaceuticals, Eli Lilly, BerGenBio, GlaxoSmithKline, Duality Biologics, and others.
Metastatic Castration-Resistant Prostate Cancer Market
Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key mCRPC companies including Sanofi, AstraZeneca, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, among others.
Colorectal Cancer Market
Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key colorectal cancer companies, including Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris, Biotherapeutics, and others.
Metastatic HR+/HER2− Breast Cancer Market
Metastatic HR+/HER2− Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic HR+/HER2− breast cancer companies, including Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research LLP